Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syros Pharmaceuticals Inc SYRS

Healthcare Biotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARa), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in... see more

Recent & Breaking News (NDAQ:SYRS)

Syros Pharmaceuticals to Present New Data on SY-1425, Its First-in-Class Potent and Selective RARα Agonist, at the ASH Annual Meeting

Business Wire November 3, 2016

Syros Announces Approval of Investigational Device Exemption (IDE) for Blood Test to Identify Cancer Patients with Proprietary Biomarkers

Business Wire October 11, 2016

Syros Announces Appointment of Gerald E. Quirk as Chief Legal Officer

Business Wire September 26, 2016

Syros Announces First Patient Enrolled in Phase 2 Clinical Trial of SY-1425 in Genomically Defined Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Business Wire September 22, 2016

Syros Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference

Business Wire September 7, 2016

Syros’ Scientific Founders Publish on First Selective CDK12 and CDK13 Inhibitor as Promising Approach for Treatment of Cancer

Business Wire August 29, 2016

Syros Pharmaceuticals to Present at BioCentury NewsMakers Conference

Business Wire August 26, 2016

Syros Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

Business Wire August 15, 2016

Syros Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

Business Wire August 3, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  July 21, 2016

Mid-Afternoon Market Update: Evoke Pharma Drops On Failed Phase 3 EVK-001 Data; ParkerVision Shares Spike Higher

Benzinga.com  July 18, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  July 15, 2016

Syros Pharmaceuticals Announces Closing of Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares

Business Wire July 6, 2016

Syros Pharmaceuticals Announces Pricing of Initial Public Offering

Business Wire June 29, 2016